Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with a major depressive episode (MDE)~* Body mass index less than or equal to 40 kg/m2~* Have been treated with an adequate dose of SSRI/SNRI during the current MDE for at least 8 weeks, with the same, adequate dose over the last 4 weeks that is expected to remain stable throughout the study~* History of inadequate response during the entire current MDE to 1 or 2 adequate antidepressant treatments, including current treatment~* Be otherwise physically healthy~Exclusion Criteria:~* Have an axis I diagnosis of delirium, dementia, amnestic or other cognitive disorder, schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder, obsessive-compulsive disorder, panic disorder, acute stress disorder, or posttraumatic stress disorder~* Have a clinically significant current axis II diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder~* Are experiencing hallucinations, delusions, or any psychotic symptomatology in the current MDE~* Receive new onset psychotherapy within 6 weeks of screening~* Use of opioid agonists (eg, codeine, oxycodone, morphine) within 14 days before screening~* Have received electroconvulsive therapy during the current MDE~* Have attempted suicide within the past 2 years~* Have a thyroid pathology~* Have a history of a seizure disorder or of neuroleptic malignant syndrome/serotonin syndrome~* Have a positive test for human immunodeficiency virus (HIV)~Additional inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ALKS 5461 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).